25 May 2013
Keywords: Hemispherx Biopharma, Ampligen, USA, FDA, CRL, Chronic fatigue syndrome
Article | 12 January 2012
Shares of USA-based Hemispherx Biopharma (NYSE Amex: HEB) rose 14% to $0.24 on Wednesday, after the company announced that the Food and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 January 2012
24 May 2013
© 2013 thepharmaletter.com